Literature DB >> 19801254

[Low-molecular-weight heparin-induced bullous haemorrhagic dermatosis associated with cell-mediated hypersensitivity].

D Thuillier1, G Chaby, A Dadban, E Dascotte, O Miquel-Christophe, M Andrejak, D Chatelain, C Lok.   

Abstract

BACKGROUND: Heparin-induced bullous hemorrhagic dermatosis is a rare, recently described side-effect of subcutaneous heparin injection. We describe a patient simultaneously presenting distant haemorrhagic bullae and eczematous reaction at the low molecular-weight heparin (LMWH) injection sites. PATIENTS AND METHODS: Subcutaneous enoxaparin sodium was initiated in a 51-year-old patient and was replaced a few days later by tinzaparin sodium. Forty-eight hours later, annular, erythematous and vesicular plaques appeared at the injection sites (thighs). Small hemorrhagic bullae were noted on the abdominal skin at the same time. Skin biopsies revealed respectively eczematous dermatitis and an intraepidermal blister filled with red blood cells. Direct immunofluorescence was negative. Standard laboratory investigations and coagulation studies were unremarkable. Skin lesions disappeared ten days after discontinuation of LMWH. Patch tests and intradermal tests were negative. DISCUSSION: The case described herein shares the stereotypical clinical picture previously reported, namely small, multiple, haemorrhagic bullae on normal skin, appearing at remote sites five to 21 days after the start of subcutaneous heparin treatment. Despite the absence of clear management guidelines, it is obviously tempting to stop the heparin if there are too many bullae for fear of more clinically significant and dangerous mucous membrane lesions. The underlying physiopathological mechanism is poorly understood; no coagulation abnormalities were recorded. In addition, our patient presented an eczematous reaction at the injection sites, raising the possibility of a type IV hypersensitivity reaction. The association of these two cutaneous side effects of heparin is perhaps not purely coincidental.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801254     DOI: 10.1016/j.annder.2008.10.037

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  5 in total

1.  Bullous hemorrhagic dermatosis due to enoxaparin use in a bullous pemphigoid patient.

Authors:  Ji-Su Shim; Soo Jie Chung; Byung-Keun Kim; Sae-Hoon Kim; Kyu Sang Lee; Yeonyee E Yoon; Yoon-Seok Chang
Journal:  Asia Pac Allergy       Date:  2017-04-26

2.  Bullous hemorrhagic dermatosis: a case report.

Authors:  Kikkeri Narayanasetty Naveen; Vijetha Rai
Journal:  Indian J Dermatol       Date:  2014-07       Impact factor: 1.494

Review 3.  Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature.

Authors:  Armand Russo; Susanna Curtis; Raisa Balbuena-Merle; Roxanne Wadia; Ellice Wong; Herta H Chao
Journal:  Exp Hematol Oncol       Date:  2018-07-06

4.  Hemorrhagic bullous dermatosis caused by warfarin therapy.

Authors:  Annie Ferguson; Spring Golden
Journal:  JAAD Case Rep       Date:  2016-04-16

5.  Bullous Hemorrhagic Dermatosis Induced by Enoxaparin.

Authors:  Isa An; Mehmet Harman; Ibrahim Ibiloglu
Journal:  Indian Dermatol Online J       Date:  2017 Sep-Oct
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.